IASLC Awards Mary J. Matthews Pathology & Transitional Research Award to Rafael Rosell at the World Conference on Lung Cancer

IASLC Awards Mary J. Matthews Pathology & Transitional Research Award to Rafael Rosell at the World Conference on Lung Cancer

Press Release
Aug 05, 2022

­­Contact: Chris Martin, IASLC Media Relations, cmartin@davidjamesgroup.com, 630.670.2745

VIENNA, Austria (August 6, 2022) ⎯ Dr. Rafael Rosell was awarded the Mary J. Matthews Pathology & Transitional Research Award today at the 2022 IASLC World Conference on Lung Cancer.

The Mary J. Matthews Pathology/Translational Research Award recognizes an IASLC scientist for lifetime achievement in pathology and translational research of thoracic malignancies. Dr. Matthews served as a senior investigator and pathologist at the National Cancer Institute’s Medical Oncology Branch. She was a pioneer in the foundation of the histologic subtypes of lung cancer and the relationship between those subtypes and the clinical course of lung cancer. 

Dr. Rafael Rosell is director of the Cancer Biology and Precision Medicine Program at the Catalan Institute of Oncology, Hospital Germans Trias i Pujol (Badalona, Barcelona, Spain), Chief Scientific Officer, Chairman and Founder of Pangaea Oncology SL (Barcelona), Chief Medical Officer and President of the Dr. Rosell Oncology Institute (IOR), Quirón Dexeus, General de Catalunya & Sagrat Cor Univ. Hospitals (Barcelona), and Founder and President of the Molecular Oncology Research Foundation (Barcelona).  

Dr. Rosell is internationally recognized for his long history of identifying, characterizing and evaluating molecular alterations in lung cancer and translating his findings to clinical trials with the goal of personalizing therapies for our patients.  

Dr. Rosell has authored more than 600 articles in scientific journals and is a highly requested speaker. 


About the IASLC

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 7,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.

About the WCLC

The WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting more than 7,000 researchers, physicians and specialists from more than 100 countries. The goal is to increase awareness, collaboration and understanding of lung cancer, and to help participants implement the latest developments across the globe. The conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit https://wclc2022.iaslc.org/